WEREWOLF THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 791.36 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-03-31 was 791.36K shares.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 0.00 shares.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-03-31 was 0.00 shares.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2026-03-31 | 791.36K shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 791.36K shares S-4 · filed 2026-09-22 | |||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-04 | 0.00 shares 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 0.00 shares 10-Q · filed 2025-08-14 | 0.00 shares 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 527.58K shares S-4 · filed 2026-09-22 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-04 | 439.00K shares 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 521.78K shares 10-Q · filed 2025-08-14 | 260.89K shares 10-Q · filed 2025-08-14 | ||
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-11 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-07 | 0.00 shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |